SCHEMBL396844

SCHEMBL396844

CC(C)(C)OC(=O)C1(C2CCCC2)CCN(C(=O)O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.37
HPGD P15428 1/20 0.35
CYP3A4 P08684 2/20 0.35
HSD17B10 Q99714 2/20 0.35
ABCB11 O95342 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CYP2D6 P10635 1/20 0.35
CHRM1 P11229 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
CHRM3 P20309 1/20 0.35
DRD1 P21728 1/20 0.35
HRH2 P25021 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20054555 0.82 CYP3A4 (0.44) EPHX1HPGDCYP3A4HSD17B10ABCB11
SCHEMBL23439148 0.80 EPHX1 (0.50) EPHX1HPGDMAPK1GPR119RECQL
SCHEMBL396843 0.79 EPHX1 (0.49) EPHX1HPGDHSD17B10MEN1KMT2A
SCHEMBL6507349 0.79 EPHX1 (0.52) EPHX1HPGDMEN1MAPK1KMT2A
SCHEMBL4609802 0.78 EPHX1 (0.51) EPHX1HPGDHSD17B10MEN1KMT2A
SCHEMBL396716 0.77 EPHX1 (0.44) EPHX1HPGDCYP3A4HSD17B10ABCB11
SCHEMBL15055467 0.76 CYP4F2 (0.40) HPGDTSHRCYP4F2CYP4A11GPR119
SCHEMBL3091643 0.76 ALDH1A1 (0.35) HPGDCYP3A4HSD17B10ABCB11LMNA
SCHEMBL2320236 0.76 CYP4F2 (0.42) EPHX1HPGDCYP4F2CYP4A11GPR119
SCHEMBL5751603 0.74 CYP4F2 (0.40) HPGDHSD17B10TSHRCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 EPHX1 2108/4885HPGD 1256/4885CYP3A4 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.